期刊文献+

香菇多糖联合化疗治疗晚期非小细胞肺癌 被引量:23

Efficacy of Lentinan combined with chemotherapy in advanced non-small cell lung cancer
下载PDF
导出
摘要 背景与目的 香菇多糖作为一种生物免疫调节剂日益受到药学界与临床的广泛重视,目前中国和日本都将其作为一种抗肿瘤辅助药品广泛应用。本研究旨在观察香菇多糖联合化疗治疗Ⅲ、Ⅳ期非小细胞肺癌的治疗效果。方法 81例Ⅲ、Ⅳ期非小细胞肺癌患者随机分为A、B两组,A组(42例)采用香菇多糖加化疗,B组(39例)采用单纯化疗。两组患者在治疗前后测定外周血T淋巴细胞亚群(CD3、CD4、CD4/CDR)和NK细胞活性,并以正常人(30例)作为对照,对患者疗效、免疫功能、生活质量及不良反应进行评价。结果 治疗后A、B两组的有效率分别为50%和33%(P<0.05);A组的T淋巴细胞亚群和NK细胞活性明显高于治疗前(P<0.01),CDR明显低于治疗前(P<0.05),而B组无明显变化(P〉0.05);A组的Karnofsky评分上升率(52%)高于B组(23%)(P〈0.01);B组的Ⅱ~Ⅳ度白细胞减少及恶心呕吐反应发生率(分别为51和44例次)高于A组(分别为39和24例次)(P<0.05)。结论香菇多糖联合化疗治疗Ⅲ、Ⅳ期非小细胞肺癌的疗效优于单纯化疗。 Background and objective Lentinus edodes polysaccharide (Lentinan) has attracted great attention from both pharmacologists and clinicians as a biological response modifier, and is widely used as an anti-tumor agent in both China and Japan. The aim of this study is to observe the efficacy of Lentinan combined with chemotherapy io stage [Ⅲ-Ⅳ non-small cell lung cancer (NSCLC). Methods Eighty-one patients with stage Ⅲ--ⅣNSCLC were randomly divided into two groups: ①Lentinan + chemotherapy group (group A, 42 cases); ②Simple chemotherapy group (group B, 39 cases). The peripheral blood T lymphocyte subsets (CD3, CD4, CD4/CD8) and natural killer (NK) cell activity of patients in both groups were measured before and after treatment, while compared with healthy control (30 cases). The immune functions, the effect of treatment, quality of life, and adverse reactions were observed. Results After treatment the objective response rate (CRWPR) was 50% in group A, compared to 33% in group B (P〈0. 05). The blood T cell levels (CD3, CD4 , CD4/CD8 ) and NK cell activity in group A increased (P〈0.01), CD8 reduced (P〈0. 05), but in group B the value had no obvious change (P〉0.05). Quality of life in group A was higher than that in group B (P〉0. 01). The incidence of grade Ⅱ-Ⅳleukopenia, nausea and vomiting in group B was much higher than those in group A (P〈0.05). Conclusion The therapeutic effect of Lentinan combined with chemotherapy is better than that of chemotherapy alone.
出处 《中国肺癌杂志》 CAS 2006年第1期78-81,共4页 Chinese Journal of Lung Cancer
关键词 香菇多糖 非小细胞肺癌 化疗/药物疗法 Lentinan Non-small cell lung cancer Chemotherapy/Drug therapy
  • 相关文献

参考文献9

  • 1Wesselius LJ,Wheaton DL,Manahan-Wahl LJ,et al.Lymphocyte subsets in lung cancer.Chest,1987,91(5):725-729.
  • 2Wasser SP.Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides.Appl Microbiol Biotechnol,2002,60(3):258-274.
  • 3Ooi VE,Liu F.Immunomodulation and anti-cancer activity of polysaccharide-protein complexes.Curr Med Chem,2000,7 (7):715-729.
  • 4Markova N,Kussovski V,Drandarska I,et al.Protective activity of Lentinan in experimental tuberculosis.Int Immunopharmacol,2003,3(10-11):1557-1562.
  • 5Kimura Y,Iijima S,Kato T,et al.Usefulness of TS-1 and lentinan combination immunochemotherapy in advanced or recurrent gastric cancer-pilot study aiming at a randomized trial.Gan To Kagaku Ryoho,2003,30(8):1125-1130.
  • 6Mushiake H,Tsunoda T,Nukatsuka M,et al.Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo.Cancer Immunol Immunother,2005,54(2):120-128.
  • 7Piao BK,Wang YX,Xie GR,et al.Impact of complementary mistletoe extract treatment on quality of life in breast,ovarian and non-small cell lung cancer patients.A prospective randomized controlled clinical trial.Anticancer Res,2004,24(1):303-309.
  • 8李柳宁,刘伟胜,徐凯,吴万垠,刘宇龙,朱迪盈,罗海英,陈春永.中医辨证施治结合化疗对中晚期非小细胞肺癌预后因子的影响[J].中国中西医结合杂志,2003,23(8):575-579. 被引量:37
  • 9Cho MY,Joh YG,Kim NR,et al.T-lymphocyte subsets in patients with AJCC stage Ⅲ gastric cancer during postoperative adjuvant chemotherapy.American Joint Committee on Cancer.Scand J Surg,2002,91(2):172-177.

二级参考文献17

  • 1郑莜萸主编.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.216-224.
  • 2孙传兴主编.I晦床疾病诊断治愈好转标准:第2版[M].北京:人民军医出版社,1998.63.
  • 3Paemans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small cell lung cancer: uni-and multivariate analysis including RECPAM in 1052 patients. J Clin Oncol 1995;13:1221-1230.
  • 4Rawson NSB, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the subcommittee for the management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Reseach. Br J Cancer 1990;61:597-604.
  • 5Sagman U, Feld R, Evans WK, et al. The prognostic significance of pretrement serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oneol 1991;9:954-961.
  • 6Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate moded based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986;46:4189-4194.
  • 7Brambilla C, Brambilla E. Lung Tumors, fundamental biology and clinical management. New York: Marcel Dekkerlnc,1999 : 157-171, 173-190, 211-225, 269-277, 347-364,365-382, 399-422, 423-433, 435-452, 583-593.
  • 8Ogawa J, Tsurumi T, Inoue H, et al. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer 1990;65:1391-1395.
  • 9Asiner J, Arriagada R, Green MR, et al. Comprehensive textbook of thoracic oneology. Baltimore: Williams & Wilkins, 1996: 25-35,276-292,319-335.
  • 10Palomares MR, 8ayre JW, Shekar KC, et al. Gender influence on weight-loss pattern and survival of non-small cell lung carcinoma patinents. Cancer 1996;78:9.119-2126.

共引文献36

同被引文献259

引证文献23

二级引证文献193

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部